The Board of Directors of BioAmber Inc. is pleased to announce the appointment of Richard P. Eno as its new Chief Executive Officer, and new member of the Board, effective September 18th, 2017. The selection of Mr. Eno caps a search process facilitated by Spencer Stuart, a global executive search firm which specializes in placing senior management personnel.
Mr. Eno has over 30 years of related management experience in the energy, chemicals, biotechnology and materials industries, including over five years as President, CEO and Board member of a publicly traded industrial biotechnology company. Rick began his career in Chevron’s chemical operations with roles of increasing responsibility in engineering, manufacturing and construction operations. He then entered management consulting where he specialized in addressing critical strategic and operational issues facing company leadership in the chemical and energy industries. In 2008, he took up leadership of Metabolix, an industrial biotechnology company commercializing a range of unique bio-based, biodegradable polymers. Most recently, Rick has been a senior partner at a global management consultancy, Roland Berger, focused on the chemicals industry.
“The Board is pleased to have found an individual with an ideal industry background as well as public company experience to assume leadership of BioAmber. Rick is uniquely qualified to lead BioAmber successfully into the future,” said Ray Land, BioAmber’s Chairman of the Board.
“I am enthused to joining the BioAmber team,” added Rick Eno. “The company’s bio-succinic technology operates superbly at scale, there is a rich pipeline of attractive customer opportunities, and a world class team in place. I look forward to leading the growth of this highly innovative company.”
Rick has a B.S. in Chemical Engineering from Cornell University, a Masters in Business Administration from the University of Houston and is a Chartered Financial Analyst (CFA). He currently serves on the President’s Council for Ceres, a non-profit promoting a sustainable future; the alumni advisory Board for Cornell University’s School of Chemical and Biomolecular Engineering; and on the alumni advisory board for Cornell’s Atkinson’s Center for a Sustainable Future.
Source: BioAmber
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
